Autoimmune Diseases: Pipelines for Crohn's Disease, Multiple Sclerosis and Rheumatoid Arthritis

This report focuses on current and pipeline candidate therapeutics and their respective targets for three autoimmune diseases and answers such questions as:

• Who are the companies with active development programs for these diseases?
• Which targets are actively being investigated and what new targets are coming forward?
• Who has candidates in active Phase III and Phase II clinical trials?
• What does the overall target activity map, from launched drug to preclinical research candidates look like?
• Where are next generation biological therapeutics found across these three diseases?
• Are small molecules a significant portion of the development activity?

• Development pipelines for each disease providing information on company and licensee involvement.
• Active Phase III and Phase II clinical trials and provide study completion dates.
• Targets involved across the spectrum of launched and preclinical activities.
• Competition among companies developing therapeutics targeting the same or related physiology.
• Pace of development activities across these three diseases.
• Small or specialty companies with innovative therapy development programs.